Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study

Journal of Infection

Volumn 81, Issue 1, 2020, Pages e1-e5

  Deng, Lisi ^a   Li, Chunna ^a   Zeng, Qi ^a   Liu, Xi ^a   Li, Xinghua ^a   Zhang, Haitang ^a   Hong, Zhongsi ^a   Xia, Jinyu ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Antiviral intervention; Arbidol; Combination therapy; Corona Virus Disease 2019; Lopinavir ritonavir

Indexed keywords

ARBIDOL; BILIRUBIN; LOPINAVIR PLUS RITONAVIR; ANTIVIRUS AGENT; INDOLE DERIVATIVE; LOPINAVIR; LOPINAVIR-RITONAVIR DRUG COMBINATION; RITONAVIR;

ADULT; ADVERSE OUTCOME; ARTICLE; BILIRUBIN BLOOD LEVEL; CLINICAL ARTICLE; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORONAVIRUS DISEASE 2019; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MALE; MONOTHERAPY; NAUSEA; OUTCOME ASSESSMENT; PLATELET COUNT; RETROSPECTIVE STUDY; THORAX RADIOGRAPHY; COMBINATION DRUG THERAPY; CORONAVIRUS INFECTION; DIAGNOSTIC IMAGING; DRUG COMBINATION; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PANDEMIC; VIRUS PNEUMONIA; X-RAY COMPUTED TOMOGRAPHY;

ADMINISTRATION, ORAL; ADULT; ANTIVIRAL AGENTS; COHORT STUDIES; CORONAVIRUS INFECTIONS; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INDOLES; LOPINAVIR; MALE; MIDDLE AGED; PANDEMICS; PNEUMONIA, VIRAL; RETROSPECTIVE STUDIES; RITONAVIR; TOMOGRAPHY, X-RAY COMPUTED;

EID: 85082430676     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2020.03.002     Document Type: Article

References (26)

1. Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., et al. Clinical characteristics of 138 hospitalized patients with 2019 Novel Coronavirus-infected pneumonia in Wuhan, China. JAMA, 2020 2020-02-07. [Epub ahead of print].
2. Zhang, J.J., Dong, X., Cao, Y.Y., Yuan, Y.D., Yang, Y.B., Yan, Y.Q., et al. Clinical characteristics of 140 patients infected by SARS-CoV-2 in Wuhan, China. Allergy, 2020 2020-02-19. [Epub ahead of print].
3. Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395:10223 (2020), 497–506 2020-02-15.
4. Lu, R., Zhao, X., Li, J., Niu, P., Yang, B., Wu, H., et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 395:10224 (2020), 565–574 2020-02-22.
5. Chan, J.F.W., Yuan, S., Kok, K.H., To, K.K.W., Chu, H., Yang, J., et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 395:10223 (2020), 514–523 2020-02-15.
6. Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 395:10223 (2020), 507–513 2020-02-15.
7. Chu, C.M., Cheng, V.C.C., Hung, I.F.N., Wong, M.M.L., Chan, K.H., Chan, K.S., et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax 59:3 (2004), 252–256 2004-03-01.
8. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected: clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected: interim guidance.
9. Chung, M., Bernheim, A., Mei, X., Zhang, N., Huang, M., Zeng, X., et al. CT imaging features of 2019 Novel Coronavirus (2019-nCoV). Radiology, 2020 2020-02-04:200230.
10. Metlay, J.P., Waterer, G.W., Long, A.C., Anzueto, A., Brozek, J., Crothers, K., et al. Diagnosis and treatment of adults with community-acquired pneumonia. an official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med 200:7 (2019), e45–e67 2019-10-01.
11. Mo, Y., Fisher, D., A review of treatment modalities for Middle East respiratory syndrome. J Antimicrob Chemother 71:12 (2016), 3340–3350 2016-12-01.
12. Khamitov, R.A., Loginova, S., Shchukina, V.N., Borisevich, S.V., Maksimov, V.A., Shuster, A.M., [Antiviral activity of arbidol and its derivatives against the pathogen of severe acute respiratory syndrome in the cell cultures]. Vopr Virusol 53:4 (2008), 9–13 2008-07-01.
13. Barnard, D.L., Kumaki, Y., Recent developments in anti-severe acute respiratory syndrome coronavirus chemotherapy. Fut Virol 6:5 (2011), 615–631 2011-05-01.
14. Peiris, J.S.M., Chu, C.M., Cheng, V.C.C., Chan, K.S., Hung, I.F.N., Poon, L.L., et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet 361:9371 (2003), 1767–1772 2003-05-24.
15. Munster, V.J., Koopmans, M., van Doremalen, N., van Riel, D., de Wit, E., A Novel Coronavirus emerging in China - key questions for impact assessment. New Engl J Med 382:8 (2020), 692–694 2020-02-20.
16. Zhou, P., Yang, X.L., Wang, X.G., Hu, B., Zhang, L., Zhang, W., et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature, 2020 2020-02-03.
17. Harmer, D., Gilbert, M., Borman, R., Clark, K.L., Quantitative mRNA expression profiling of ACE 2, a novel homologue of angiotensin converting enzyme. FEBS Lett 532:1–2 (2002), 107–110 2002-12-04.
18. Boriskin, Y.S., Leneva, I.A., Pecheur, E.I., Polyak, S.J., Arbidol: a broad-spectrum antiviral compound that blocks viral fusion. Curr Med Chem 15:10 (2008), 997–1005 2008-01-20.
19. Cvetkovic, R.S., Goa, K.L., Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs 63:8 (2003), 769–802 2003-01-20.
20. Blaising, J., Polyak, S.J., Pecheur, E.I., Arbidol as a broad-spectrum antiviral: an update. Antiviral Res 107 (2014), 84–94 2014-07-01.
21. Molina, J.M., Andrade-Villanueva, J., Echevarria, J., Chetchotisakd, P., Corral, J., David, N., et al. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the Castle study. Lancet 372:9639 (2008), 646–655 2008-08-23.
22. Stockman, L.J., Bellamy, R., Garner, P., SARS: systematic review of treatment effects. Plos Med, 3(9), 2006, e343 2006-09-01.
23. Arabi, Y.M., Mandourah, Y., Al-Hameed, F., Sindi, A.A., Almekhlafi, G.A., Hussein, M.A., et al. Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome. Am J Respir Crit Care Med 197:6 (2018), 757–767 2018-03-15.
24. Public Health England, International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC). Clinical decision making tool for treatment of MERS-CoV.
25. Xu, Z., Shi, L., Wang, Y., Zhang, J., Huang, L., Zhang, C., et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med, 2020 2020-02-18.
26. Omrani, A.S., Saad, M.M., Baig, K., Bahloul, A., Abdul-Matin, M., Alaidaroos, A.Y., et al. Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study. Lancet Infect Dis 14:11 (2014), 1090–1095 2014-11-01.